CYBN trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CYBN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Cybin Inc. (CYBN) has a Wall Street consensus price target of N/A, based on estimates from 4 covering analysts. The company has a market capitalization of $304M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CYBN trades at a trailing P/E of -13.7x. Analysts expect EPS to grow +20.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 CMPSCOMPASS Pathways plc | $1.9B | $13.75 | $18.63 | +35.5% | Buy | — | 15 |
 MNMDMind Medicine (MindMed) Inc. | $3.2B | $42.79 | $20.00 | -53.3% | Buy | — | 1 |
 ATAIAtai Beckley Inc. | $2.7B | $7.35 | $7.69 | +4.6% | Hold | — | 8 |
 SILOSilo Pharma, Inc. | $2M | $1.77 | — | — | — | — | — |
 HALOHalozyme Therapeutics, Inc. | $13.3B | $112.44 | $103.00 | -8.4% | Buy | 13.4x | 27 |
 ENVBEnveric Biosciences, Inc. | $934324 | $1.56 | — | — | — | — | — |
 MAPSWM Technology, Inc. | $41M | $0.37 | — | — | — | — | — |
 INVAInnoviva, Inc. | $1.5B | $20.24 | $38.00 | +87.7% | Buy | 8.2x | 10 |
 NVAXNovavax, Inc. | $1.7B | $10.55 | $18.00 | +70.6% | Buy | — | 23 |
 PRLDPrelude Therapeutics Incorporated | $338M | $4.31 | $8.00 | +85.6% | Buy | — | 8 |
Quick answers to the most common questions about buying CYBN stock.
The consensus price target for CYBN is $N/A, close to the current price of $6.09 (N/A% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
CYBN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
CYBN's current price is $6.09 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for CYBN, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
CYBN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CYBN stock forecast based on 4 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
CYBN appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CYBN analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.